PUBLISHER: DelveInsight | PRODUCT CODE: 1462270
PUBLISHER: DelveInsight | PRODUCT CODE: 1462270
"NE-3107 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about NE-3107 for Parkinson's disease in the seven major markets. A detailed picture of the NE-3107 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NE-3107 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NE-3107 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
NE-3107 is a novel orally administered small molecule that selectively inhibits the inflammatory ERK signaling and thereby reduces neuroinflammation, inhibit inflammation-driven insulin resistance, and other major pathological inflammatory cascades.
The recently completed Phase I/II trial of NE3107 for treating Parkinson's disease depicted positive results and the company will present these results at the International Conference on Alzheimer's and Parkinson's Diseases to be held in 2023 as the data from Phase II Parkinson's Disease trial is accepted for the presentation. BioVie plans to initiate the pivotal Phase IIb trial SUNRISE-1 in 3Q2023, and SUNRISE-2 is a potentially pivotal Phase III starting late 1Q2024.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
NE-3107 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of NE-3107 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of NE-3107 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.